GP2 is an MHC class I recognizing immunogenic peptide obtained from the intracellular domain of HER2 protein and has been shown to induce strong CD8+ T cell-mediated antitumor response in HER2+ BC (154). This evidence concerns the gene CD8A and breast cancer.